Core Viewpoint - The announcement by the company indicates that its drug Enze Shu® (suvorexant injection) has been officially included in the National Medical Insurance Catalog for 2025, effective from January 1, 2026, which is a significant milestone for the company and its product portfolio [1][4]. Group 1: Drug Approvals and Listings - Enze Shu® has been approved for the treatment of adult patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received no more than one prior systemic therapy and are platinum-resistant [1][4]. - The drug was granted market approval in China on June 30, 2025, marking its entry into the competitive oncology market [1][4]. - The company’s other drug, Endu® (recombinant human vascular endothelial growth factor inhibitor injection), has successfully completed its renewal in the National Reimbursement Drug List (NRDL) [1][4]. Group 2: Market Position and Significance - Enze Shu® is described as a next-generation recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), highlighting its innovative nature in cancer treatment [1][4]. - Endu® is noted as the first anti-angiogenic targeted drug in China and the only endothelial inhibitor approved for sale globally, establishing its importance in the treatment of advanced non-small cell lung cancer since its inclusion in the NRDL in 2017 [1][4].
先声药业：恩泽舒®与恩度®纳入新版国家医保药品目录